$242 Million is the total value of Endurant Capital Management LP's 73 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | New | PFIZER INC | $4,518,000 | – | 139,100 | +100.0% | 1.87% | – |
| EVHC | New | ENVISION HEALTHCARE CORP | $3,538,000 | – | 55,900 | +100.0% | 1.46% | – |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $3,327,000 | – | 86,400 | +100.0% | 1.38% | – |
| HSIC | New | SCHEIN HENRY INC | $3,216,000 | – | 21,200 | +100.0% | 1.33% | – |
| LLY | New | LILLY ELI & CO | $2,802,000 | – | 38,100 | +100.0% | 1.16% | – |
| New | FLUIDIGM CORP DELnote 2.750% 2/0 | $2,183,000 | – | 3,161,000 | +100.0% | 0.90% | – | |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $1,788,000 | – | 16,400 | +100.0% | 0.74% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $1,483,000 | – | 44,800 | +100.0% | 0.61% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $993,000 | – | 10,600 | +100.0% | 0.41% | – |
| PPH | New | VANECK VECTORS ETF TRpharmaceutical e | $819,000 | – | 15,600 | +100.0% | 0.34% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $808,000 | – | 2,200 | +100.0% | 0.33% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $230,000 | – | 8,400 | +100.0% | 0.10% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $224,000 | – | 56,800 | +100.0% | 0.09% | – |
| GLYC | New | GLYCOMIMETICS INC | $88,000 | – | 14,500 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.